Long-Term Effectiveness of Medtronic's Blood Pressure Procedure
Medtronic plc (NYSE: MDT), a leader in healthcare technology, recently showcased remarkable findings from the SPYRAL HTN-ON MED clinical trial. This trial presented long-term data demonstrating sustained and significant reductions in blood pressure in patients undergoing the Symplicity™ renal denervation (RDN) procedure. These promising results reinforce the safety and efficiency of this innovative approach in managing hypertension, particularly for those reliant on antihypertensive medications.
Significant Findings from the SPYRAL HTN-ON MED Trial
During the SPYRAL HTN-ON MED trial, participants receiving the Symplicity RDN treatment experienced more substantial reductions in blood pressure compared to those in the sham group over a three-year period. This rigorous clinical evaluation revealed noteworthy differences at the three-year mark:
- 24-hour ambulatory systolic blood pressure (ABPM): The RDN group showed an impressive decrease of ?14.0 mmHg, while the sham group recorded a reduction of only ?9.3 mmHg.
- Office-based systolic blood pressure (OSBP): Patients treated with RDN had an average decrease of ?18.5 mmHg, compared to ?11.7 mmHg in the sham group. These outcomes signify a treatment difference of ?4.7 mmHg for ABPM and ?7.4 mmHg for OSBP, with notable statistical significance (p=0.0028 and p=0.0002, respectively).
Safety and Long-Term Implications
A key highlight from this trial was the safety profile of the Symplicity RDN system. No instances of renal artery stenosis exceeding 70% were reported in the RDN cohort throughout the study duration. These results help establish the long-term safety of the procedure, contributing to greater confidence among healthcare providers regarding its use for managing resistant hypertension.
Expert Insights on the Results
Dr. David Kandzari, the chief of Piedmont Heart Institute and co-principal investigator of the SPYRAL clinical program, emphasized the significance of these findings, stating that radiofrequency renal denervation effectively maintains blood pressure reduction over the long term. Furthermore, the results highlight the therapeutic advantage for patients who face challenges in achieving desired blood pressure levels through medications alone.
About Medtronic
Medtronic is driven by a mission to alleviate pain, restore health, and extend life. Headquartered in Galway, Ireland, the company exemplifies innovation in medical technology with a diverse range of products that cater to various health conditions. With over 95,000 employees spread across more than 150 countries, Medtronic is at the forefront of delivering transformative healthcare solutions, improving patient outcomes, and enhancing overall quality of life worldwide.
Frequently Asked Questions
What is the SPYRAL HTN-ON MED trial?
The SPYRAL HTN-ON MED trial is a randomized, sham-controlled study investigating the long-term effects and safety of renal denervation on patients with resistant hypertension.
What were the key findings from the trial?
Patients treated with the Symplicity RDN procedure showed significant reductions in both 24-hour ambulatory and office-based systolic blood pressure compared to sham patients.
How safe is the Symplicity RDN system?
The trial reported no occurrences of renal artery stenosis greater than 70% in the RDN group, indicating a strong long-term safety profile for the system.
Who is Medtronic?
Medtronic is a global leader in healthcare technology, dedicated to tackling the toughest health issues with innovative solutions aimed at enriching lives.
What is the mission of Medtronic?
Medtronic's mission centers around alleviating pain, restoring health, and extending life through leading-edge medical technology and patient care solutions.
